CURA_1170x120_8-22-19

Hospira

FDA approves Inflectra, the second U.S. biosimilar

FDA approves Inflectra, the second U.S. biosimilar

WASHINGTON — Just over a year after approving its first biosimilar product, the Food and Drug Administration has approved its second, Celltrion’s Inflectra (biosimilar infliximab). Inflectra is a biosimilar to Janssen Biotech’s Remicade (infliximab), originally licensed in 1998. Inflectra is indicated for reducing signs and symptoms in patients with rheumatoid arthritis, adult ulcerative colitis, plaque

Alvogen to acquire four products from Pfizer

Alvogen to acquire four products from Pfizer

PINE BROOK, N.J. — Alvogen has entered an agreement to buy a portfolio of four U.S. pharmaceutical products from Pfizer Inc. Under the deal announced Wednesday, Alvogen plans to acquire three injectable products — Clindamycin, Voriconazole and Melphalan — and one inhaled solution product, Acetylcysteine. Financial terms of the deal weren’t disclosed. Two of the